Hydrophilic Nasal Gel of Lidocaine Hydrochloride

Abstract Intranasal lidocaine hydrochloride (LID, CAS 73-78-9) has been shown useful in the control of a series of symptoms such as migraine, cluster headache and trigeminal neuralgia in clinical studies. However, rapid nasal mucociliary clearance of intranasal solution usually affects its efficiency. In this study, a nasal gel formulation was designed using hydroxy-propyl methyl cellulose (HPMC) as mu-coadhesive polymer to increase the residence time of LID on the nasal mucosa. Based on the results of a preliminary single factor study, the gel formulation was optimized by central composite design to provide better drug release and bioadhe-sive intensity. The methods for investigating the gel’s bioadhesive intensity and for spectrophotometric determination of LID were established. Then the parameters for the LID in vitro release study such as release medium, release apparatus and rotation rate were decided upon a method of f2 fit factor. The in vitro drug release property of the optimized formulation was proved to comply with the Higuchi equation.

[1]  S. Hoka,et al.  Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. , 2006, British journal of anaesthesia.

[2]  R. Kinget,et al.  Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. , 2005, Advanced drug delivery reviews.

[3]  D. Craig,et al.  An in vitro mucosal model for prediction of the bioadhesion of alginate solutions to the oesophagus. , 2002, International journal of pharmaceutics.

[4]  L. Illum.  Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  M. Maizels,et al.  Intranasal Lidocaine for Migraine: A Randomized Trial and Open‐Label Follow‐up , 1999, Headache.

[6]  Y. Aramaki,et al.  Drug release from pH-response polyvinylacetal diethylaminoacetate hydrogel, and application to nasal delivery , 1998 .

[7]  Yi Tsong,et al.  In Vitro Dissolution Profile Comparison—Statistics and Analysis of the Similarity Factor, f2 , 1998, Pharmaceutical Research.

[8]  N. Xi,et al.  [Toxicity of drugs on nasal mucocilia and the method of its evaluation]. , 1995, Yao xue xue bao = Acta pharmaceutica Sinica.

[9]  J. Sandweiss,et al.  Rapid and Sustained Relief of Migraine Attacks With Intranasal Lidocaine: Preliminary Findings , 1995, Headache.

[10]  C T Hung,et al.  Optimized synthesis of polyglutaraldehyde nanoparticles using central composite design. , 1988, Journal of pharmaceutical sciences.

[11]  G. Daculsi,et al.  Engineering cartilage with human nasal chondrocytes and a silanized hydroxypropyl methylcellulose hydrogel. , 2007, Journal of biomedical materials research. Part A.

[12]  S. Tepper,et al.  Intranasal Medications for the Treatment of Migraine and Cluster Headache , 2004, CNS drugs.

[13]  U. Kompella,et al.  Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? , 1998, Journal of drug targeting.